Characteristics of minimally invasive surgery patients in study, not in study, and those deceased
| Characteristic | In study | Not in study | Deceased at time of mailing | P* |
| n=221 | n=204 | n=27 | ||
| At the time of the surgery | ||||
| Age (years), mean (SD) | 64.7 (8.9) | 63.7 (10.4) | 72.8 (11.5) | 0.27 |
| BMI (kg/m2), median (IQR) | 32.9 (27.6–38.6) | 34.7 (27.9–41.2) | 29.3 (27.5–38.6) | 0.05 |
| BMI (kg/m2), N (%) | 0.04 | |||
| <25.0 | 29 (13.1) | 28 (13.7) | 4 (14.8) | |
| 25.0–29.9 | 54 (24.4) | 35 (17.2) | 10 (37.0) | |
| 30.0–39.9 | 95 (43.0) | 79 (38.7) | 10 (37.0) | |
| 40.0 or higher | 43 (19.5) | 62 (30.4) | 3 (11.1) | |
| ASA score, N (%) | 0.01 | |||
| <3 | 171 (77.4) | 136 (66.7) | 14 (51.9) | |
| ≥3 | 50 (22.6) | 68 (33.3) | 13 (48.1) | |
| Comorbidities, N (%) | ||||
| Diabetes | 31 (14.0) | 35 (17.2) | 5 (18.5) | 0.37 |
| Chronic heart failure | 6 (2.7) | 2 (1.0) | 3 (11.1) | 0.29 |
| Moderate/severe renal disease | 4 (1.8) | 6 (2.9) | 2 (7.4) | 0.53 |
| Surgical details | ||||
| FIGO grade, N (%) | 0.89 | |||
| 1 | 111 (50.2) | 99 (48.5) | 4 (14.8) | |
| 2 | 51 (23.1) | 51 (25.0) | 5 (18.5) | |
| 3 | 59 (26.7) | 54 (26.5) | 18 (66.7) | |
| FIGO stage, N (%) | 0.36 | |||
| I/II | 202 (91.4) | 181 (88.7) | 11 (40.7) | |
| III/IV | 19 (8.6) | 23 (11.3) | 16 (59.3) | |
| Histology, N (%)† | 0.62 | |||
| Non-endometrioid | 35 (15.8) | 36 (17.6) | 13 (48.1) | |
| Endometrioid | 186 (84.2) | 168 (82.4) | 14 (51.9) | |
| Study group, N (%) | 0.74 | |||
| LND | 101 (45.7) | 90 (44.1) | 13 (48.1) | |
| SLN | 120 (54.3) | 114 (55.9) | 14 (51.9) | |
| Total nodes removed via SLN among those with nodes removed, median (IQR) | 3 (2–4) | 3 (2–4) | 3 (1–3) | 0.85 |
| LND performed, N (%) | 0.21 | |||
| No | 103 (46.6) | 91 (44.6) | 13 (48.1) | |
| Pelvic only | 69 (31.2) | 74 (36.3) | 4 (14.8) | |
| Para-aortic only | 2 (0.9) | 6 (2.9) | – | |
| Pelvic and para-aortic | 47 (21.3) | 33 (16.2) | 10 (37.0) | |
| Total nodes removed via LND among those with nodes removed, median (IQR) | ||||
| Total pelvic and para-aortic | 24 (16–31) | 21 (14–32) | 22 (18–24) | 0.34 |
| Total pelvic | 20 (15–26) | 20 (14–26) | 14 (10–20) | 0.83 |
| Total para-aortic | 10 (7–18) | 10 (6–16) | 9 (3–10) | 0.70 |
| Total nodes removed by any means (SLN+LND), median (IQR) | 9 (4–26) | 9 (3–24) | 6 (3–22) | 0.80 |
| Adjuvant therapy, N (%) | 0.02 | |||
| None or VB alone | 184 (83.3) | 160 (78.4) | 11 (40.7) | |
| EBRT±VB | 3 (1.4) | 1 (0.5) | 2 (7.4) | |
| Chemotherapy±VB | 21 (9.5) | 13 (6.4) | 5 (18.5) | |
| Chemotherapy and EBRT±VB | 8 (3.6) | 13 (6.4) | 5 (18.5) | |
| Unknown | 5 (2.3) | 17 (8.3) | 4 (14.8) |
*Comparison between ‘In study’ and ‘Not in study’ only; comparisons were evaluated using the two-sample t-test for age, Wilcoxon rank-sum test for all other continuous or ordinal variables, and χ2 or Fisher’s exact for categorical variables. P<0.05 was considered statistically significant.
†Endometrioid histology includes endometrioid and mixed endometrioid and mucinous histology; non-endometrioid histology includes serous, clear cell, carcinosarcoma, undifferentiated, mixed serous, mixed clear cell, and mixed undifferentiated histology.
ASA, American Society of Anesthesiologists; BMI, body mass index; EBRT, external beam radiation therapy; FIGO, International Federation of Gynecology and Obstetrics; IQR, interquartile range (25th and 75th percentiles); LND, lymphadenectomy; SLN, sentinel lymph node sampling; VB, vaginal brachytherapy.